FDA Advisers Convinced by Benefits of Geron's Imetelstat for Blood Disorder Drug

Thursday, 14 March 2024, 21:37

FDA advisers expressed overwhelming support for Geron's blood disorder drug, imetelstat, after a successful late-stage trial. With a 12-to-2 vote, the panel favored the benefits of the treatment, emphasizing the manageable risks and toxicities associated with the injectable drug. Geron aims to gain FDA approval for using imetelstat to treat transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS).
https://store.livarava.com/10186606-e24d-11ee-9671-5254a2021b2b.png
FDA Advisers Convinced by Benefits of Geron's Imetelstat for Blood Disorder Drug

Overview

FDA advisers endorsed the benefits of Geron's imetelstat for treating blood disorders.

Key Points:

  • Supportive Vote: 12-to-2 margin in favor of imetelstat's benefits.
  • Risk Management: Emphasis on manageable risks and toxicities of the injectable drug.
  • Targeted Treatment: Approval sought for transfusion-dependent anemia in myelodysplastic syndromes patients.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe